Clinical Trial Detail

NCT ID NCT03628716
Title CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bavarian Nordic
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Atezolizumab + CV301

Age Groups: adult senior

No variant requirements are available.